CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$6.60 USD
-0.03 (-0.38%)
Updated Jul 26, 2024 03:59 PM ET
After-Market: $6.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CASI 6.60 -0.03(-0.38%)
Will CASI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CASI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CASI
CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
USANA Health Sciences (USNA) Q3 Earnings Miss Estimates
CASI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Revised)
ProPhase Labs, Inc. (PRPH) Reports Q2 Loss, Lags Revenue Estimates
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates
Other News for CASI
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
CASI Pharmaceuticals Freezes Juventas Assets Amid Dispute
CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP
Biotech Alert: Searches spiking for these stocks today
CASI Pharmaceuticals Secures $15M in Funding